Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India ・Tirzepatide is used to manage type 2 ...

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...

Cipla shares drop 3.7% after Eli Lilly deal, but analysts see strong growth in India's obesity market—learn more about the ...

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Cipla enters obesity and diabetes drug market with Eli Lilly's tirzepatide 'Yurpeak'; Nuvama retains 'Hold' on Cipla stock, ...

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...

Eli Lilly signed an agreement with Cipla, allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Eli Lilly has signed a licensing deal with Cipla to market its blockbuster weight-loss drug under the brand name Yurpeak in ...

Lilly and Cipla announce a distribution agreement for Yurpeak, a drug for type 2 diabetes and weight management, enhancing ...